Skip to main content

Table 1 Comparison of clinical and laboratory features between SOX30 hypermethylated and non-hypermethylated AML patients

From: Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies

Patient’s features Total
(n = 196)
Non-hypermethylated
(n = 96)
Hypermethylated
(n = 100)
P value
Sex, male/female 114/82 58/38 56/44 0.564
Median age, years (range) 57 (18–86) 52 (18–83) 59 (18–86) 0.024
Median WBC, × 109/L (range) 14.35 (0.3–528.0) 11.35 (0.3–528.0) 15.75 (0.3–249.3) 0.554
Median hemoglobin, g/L (range) 77 (32–147) 75 (34–147) 78 (32–144) 0.536
Median platelets, ×109/L (range) 42.5 (3–447) 43 (3–447) 42 (3–399) 0.521
Median BM blasts, % (range) 49.75 (1.0a–99.0) 49.5 (1.0a–97.5) 50.5 (5.5a–99.0) 0.173
FAB classifications     0.005
 M0 2 0 (0%) 2 (2%)  
 M1 18 11 (11%) 7 (7%)  
 M2 83 35 (36%) 48 (48%)  
 M3 28 22 (23%) 6 (6%)  
 M4 37 17 (18%) 20 (20%)  
 M5 20 10 (10%) 10 (10%)  
 M6 6 1 (1%) 5 (5%)  
 No data 2 0 (0%) 2 (2%)  
Karyotypes     0.020
 Normal 95 39 (41%) 56 (56%)  
t(8;21) 14 10 (10%) 4 (4%)  
 inv.(16) 2 1 (1%) 1 (1%)  
t(15;17) 27 21 (22%) 6 (6%)  
 + 8 6 2 (2%) 4 (4%)  
 -5/5q- 1 1 (1%) 0 (0%)  
 -7/7q- 2 0 (0%) 2 (2%)  
t(9;22) 2 1 (1%) 1 (1%)  
 11q23 2 0 (0%) 2 (2%)  
 Complex 17 8 (8%) 9 (9%)  
 Others 16 8 (8%) 8 (8%)  
 No data 12 5 (5%) 7 (7%)  
Gene mutations     
CEBPA (+/−) 23/137 10/68 13/69 0.656
NPM1 (+/−) 17/143 8/70 9/73 > 0.999
FLT3-ITD (+/−) 15/145 5/73 10/72 0.280
C-KIT (+/−) 10/150 6/72 4/78 0.527
N/K-RAS (+/−) 15/145 7/71 8/74 > 0.999
IDH1/2 (+/−) 10/150 2/76 8/74 0.099
DNMT3A (+/−) 8/152 3/75 5/77 0.720
U2AF1 (+/−) 5/155 2/76 3/79 > 0.999
SRSF2 (+/−) 5/155 2/76 3/79 > 0.999
CR (+/−) 75/93 47/41 28/52 0.020
  1. WBC white blood cells, BM bone marrow, FAB French-American-British classification, CR complete remission
  2. aPatients’ blasts less than 20% with t(15;17) cytogenetic aberrations